BioLife Solutions Swings to Q3 Profit, Revenue Jumps 31%

TL;DR

**BLFS is showing signs of a turnaround with strong revenue growth and a Q3 profit, but watch cash burn and continued losses over the longer nine-month period.**

AI Summary

BioLife Solutions, Inc. (BLFS) reported a significant increase in total revenue for the three and nine months ended September 30, 2025. Total product, rental, and service revenue grew to $28.067 million for the three months ended September 30, 2025, up from $21.391 million in the prior year, representing a 31.2% increase. For the nine months ended September 30, 2025, total revenue reached $77.429 million, a 30.1% increase from $59.539 million in the same period of 2024. The company achieved a net income of $0.621 million for the three months ended September 30, 2025, a substantial improvement from a net loss of $1.703 million in the prior year. However, for the nine-month period, BLFS reported a net loss of $15.665 million, though this is an improvement from the $32.643 million net loss in the comparable 2024 period. Key business changes include the acquisition of the remaining 90% of PanTHERA CryoSolutions Inc. on April 4, 2025, and the subsequent divestiture of SAVSU Cleo Technologies, LLC on October 6, 2025, which is treated as a subsequent event. Risks include significant operating losses, with a nine-month operating loss of $17.949 million in 2025, and a substantial decrease in cash and cash equivalents from $95.386 million at December 31, 2024, to $29.481 million at September 30, 2025. The strategic outlook focuses on bioproduction products and services for the cell and gene therapy industry, with recent divestitures streamlining operations.

Why It Matters

BioLife Solutions' return to profitability in Q3 2025 and robust revenue growth signal potential operational improvements and market traction in the critical cell and gene therapy (CGT) sector. For investors, the significant reduction in net loss for the nine-month period, coupled with strategic divestitures like SAVSU, suggests a focused approach to core biopreservation and thawing solutions, potentially enhancing long-term value. Employees and customers in the CGT space benefit from BLFS's specialized products, which are vital for de-risking biologic manufacturing and distribution, fostering innovation and patient access. In a competitive landscape, BLFS's ability to grow revenue while streamlining its portfolio could position it as a more agile and specialized player.

Risk Assessment

Risk Level: medium — The company reported a net loss of $15.665 million for the nine months ended September 30, 2025, and a significant decrease in cash and cash equivalents from $95.386 million at December 31, 2024, to $29.481 million at September 30, 2025. This substantial cash reduction, coupled with an operating loss of $17.949 million for the nine-month period, indicates ongoing financial challenges despite the Q3 net income.

Analyst Insight

Investors should closely monitor BioLife Solutions' cash flow and operating expenses in upcoming quarters to ensure the Q3 profitability trend is sustainable. The strategic divestitures are positive for focus, but the significant cash burn over nine months warrants caution. Consider if the company's core biopreservation products can drive consistent, profitable growth.

Financial Highlights

debt To Equity

0.02

revenue

$77,429,000

operating Margin

N/A

total Assets

$392,081,000

total Debt

$7,492,000

net Income

$621,000

eps

N/A

gross Margin

N/A

cash Position

$29,481,000

revenue Growth

+30.1%

Revenue Breakdown

Key Numbers

• $28.067M — Total Revenue (Q3 2025) (Increased 31.2% from $21.391M in Q3 2024)
• $77.429M — Total Revenue (9M 2025) (Increased 30.1% from $59.539M in 9M 2024)
• $0.621M — Net Income (Q3 2025) (Swung from a net loss of $1.703M in Q3 2024)
• ($15.665M) — Net Loss (9M 2025) (Improved from a net loss of $32.643M in 9M 2024)
• $29.481M — Cash and Cash Equivalents (Sep 30, 2025) (Decreased significantly from $95.386M at Dec 31, 2024)
• ($17.949M) — Operating Loss (9M 2025) (Increased from an operating loss of $5.019M in 9M 2024)
• 48,148,046 — Common Shares Outstanding (As of October 30, 2025)
• 31.2% — Q3 Revenue Growth (Year-over-year increase in total product, rental, and service revenue)
• 30.1% — 9M Revenue Growth (Year-over-year increase in total product, rental, and service revenue)
• $15.199M — Net Cash Provided by Operating Activities (9M 2025) (Increased from $6.786M in 9M 2024)

Key Players & Entities

• BioLife Solutions, Inc. (company) — registrant
• PanTHERA CryoSolutions Inc. (company) — acquired company
• SAVSU Cleo Technologies, LLC (company) — divested entity
• Peli BioThermal LLC (company) — buyer of SAVSU
• Casdin Partners Master Fund L.P. (company) — seller in PanTHERA acquisition
• Dr. Jason Acker (person) — Sellers' Representative for PanTHERA acquisition
• The Nasdaq Stock Market, LLC (regulator) — exchange where BLFS common stock is registered
• $28.067 million (dollar_amount) — total revenue for three months ended September 30, 2025
• $77.429 million (dollar_amount) — total revenue for nine months ended September 30, 2025
• $0.621 million (dollar_amount) — net income for three months ended September 30, 2025

FAQ

Risk Factors

• Significant Operating Losses and Cash Burn [high — financial]: The company reported a nine-month operating loss of $17.949 million for 2025, an increase from $5.019 million in the prior year. Cash and cash equivalents decreased substantially from $95.386 million at December 31, 2024, to $29.481 million at September 30, 2025, indicating a significant burn rate.
• Dependence on Cell and Gene Therapy Market [high — operational]: BioLife's business is heavily reliant on the growth and success of the cell and gene therapy (CGT) industry. Any slowdown or setbacks in this nascent market could materially impact demand for BioLife's bioproduction products and services.
• Integration of Acquisitions [medium — operational]: The acquisition of PanTHERA CryoSolutions Inc. on April 4, 2025, requires successful integration to realize synergies. Failure to effectively integrate acquired businesses could disrupt operations and hinder growth.
• Competition in Biopreservation Market [medium — market]: The market for biopreservation media and related products is competitive. BioLife faces competition from established players and new entrants, which could pressure pricing and market share.
• Net Loss for Nine-Month Period [medium — financial]: Despite revenue growth, the company incurred a net loss of $15.665 million for the nine months ended September 30, 2025. While an improvement from the prior year's loss of $32.643 million, sustained unprofitability poses a risk.
• Divestiture of SAVSU Cleo Technologies [low — operational]: The divestiture of SAVSU Cleo Technologies, LLC on October 6, 2025, while streamlining operations, means the company is no longer generating revenue from its 'evo' shipping container products. This strategic shift requires focus on core bioproduction offerings.

Industry Context

BioLife Solutions operates within the life sciences sector, specifically focusing on the rapidly growing cell and gene therapy (CGT) market. This industry requires specialized bioproduction tools and services for manufacturing, distribution, and transportation of sensitive biologic materials. Key competitors offer a range of solutions, but BioLife differentiates itself with proprietary media, automated devices, and specialized containers designed to de-risk biologic manufacturing.

Regulatory Implications

The CGT industry is subject to stringent regulatory oversight by bodies like the FDA. BioLife's products, used in the manufacturing and transport of therapies, must meet high-quality and safety standards. Compliance with Good Manufacturing Practices (GMP) and other regulations is crucial for market access and customer trust.

What Investors Should Do

1. Monitor cash burn and path to profitability.
2. Assess integration of PanTHERA CryoSolutions.
3. Evaluate impact of SAVSU divestiture.
4. Track revenue growth drivers.

Key Dates

• 2025-04-04: Acquisition of remaining 90% of PanTHERA CryoSolutions Inc. — Expands BioLife's portfolio in the CGT bioproduction space, potentially enhancing its market position.
• 2025-09-30: End of the third quarter and nine-month period — Reporting period for the financial results, showing significant revenue growth but continued net loss.
• 2025-10-06: Divestiture of SAVSU Cleo Technologies, LLC — Streamlines operations by selling the 'evo' shipping container business, focusing resources on core bioproduction products and services.
• 2025-10-30: Common Shares Outstanding reported — Provides an updated share count for potential per-share calculations and market capitalization assessment.

Glossary

Cell and Gene Therapy (CGT)

A rapidly advancing field of medicine that uses genes or cells to treat diseases, often involving complex manufacturing and preservation requirements. (BioLife's primary target market, driving demand for its specialized products and services.)

Biopreservation Media

Specialized solutions designed to maintain the viability and integrity of biological materials, such as cells, during storage and transport. (Core product offering for BioLife, including CryoStor and HypoThermosol.)

Automated Thawing Devices

Equipment that standardizes and controls the thawing process for frozen cell and gene therapies, reducing risks associated with manual methods. (Key product line (ThawSTAR) that addresses critical steps in biologic therapy administration.)

Accumulated Deficit

The cumulative net losses of a company over its lifetime that have not been offset by net income. (Indicates the company has historically operated at a net loss, with a deficit of $350.766 million as of September 30, 2025.)

Available-for-sale securities

Investments in debt or equity securities that are not classified as held-to-maturity or trading securities; they are reported at fair value. (Represents a significant portion of current assets ($49.473 million) and long-term assets ($19.444 million), impacting liquidity and investment strategy.)

Year-Over-Year Comparison

Compared to the prior year, BioLife Solutions has demonstrated robust revenue growth, with total product, rental, and service revenue increasing by 31.2% in Q3 2025 and 30.1% for the nine-month period. This top-line expansion has led to a swing from a net loss to net income in the third quarter. However, the company's cash position has significantly declined from $95.386 million to $29.481 million, and operating losses for the nine-month period have widened substantially, indicating ongoing investment and operational costs.

Key Financial Figures

• $0.001 — ich registered Common stock, par value $0.001 per share BLFS The Nasdaq Stock Market,

Filing Documents

• blfs-20250930.htm (10-Q) — 1585KB
• exhibit311-q32025.htm (EX-31.1) — 10KB
• exhibit312-q32025.htm (EX-31.2) — 10KB
• exhibit321-q32025.htm (EX-32.1) — 4KB
• exhibit322-q32025.htm (EX-32.2) — 4KB
• blfs-20250930_g1.jpg (GRAPHIC) — 13KB
• 0001628280-25-050190.txt ( ) — 10189KB
• blfs-20250930.xsd (EX-101.SCH) — 81KB
• blfs-20250930_cal.xml (EX-101.CAL) — 116KB
• blfs-20250930_def.xml (EX-101.DEF) — 396KB
• blfs-20250930_lab.xml (EX-101.LAB) — 873KB
• blfs-20250930_pre.xml (EX-101.PRE) — 650KB
• blfs-20250930_htm.xml (XML) — 1662KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 3 Item 1. Unaudited Condensed Consolidated Financial Statements 3 Unaudited Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 3 Unaudited Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2025 and 2024 4 Unaudited Condensed Consolidated Statements of Comprehensive Income ( Loss ) for the three and nine months ended September 30, 2025 and 2024 7 Unaudited Condensed Consolidated Statements of Shareholders' Equity for the three and nine months ended September 30, 2025 and 2024 8 Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 10 Notes to Unaudited Condensed Consolidated Financial Statements 12 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 40 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 47 Item 4.

Controls and Procedures

Controls and Procedures 47

OTHER INFORMATION

PART II. OTHER INFORMATION 49 Item 1.

Legal Proceedings

Legal Proceedings 49 Item 1A.

Risk Factors

Risk Factors 49 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 49 Item 3. Defaults Upon Senior Securities 49 Item 4. Mine Safety Disclosures 49 Item 5. Other Information 49 Item 6. Exhibits 50

Signatures

Signatures 51 2 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements BioLife Solutions, Inc. Unaudited Condensed Consolidated Balance Sheets September 30, December 31, (In thousands, except per share and share data) 2025 2024 Assets Current assets: Cash and cash equivalents $ 29,481 $ 95,386 Available-for-sale securities, current portion 49,473 9,198 Accounts receivable, trade, net of allowance for credit losses of $ 105 and $ 153 as of September 30, 2025 and December 31, 2024, respectively 10,842 9,168 Inventories 27,825 29,013 Prepaid expenses and other current assets 8,945 5,996 Total current assets 126,566 148,761 Assets held for rent, net 5,164 6,103 Property and equipment, net 11,101 6,084 Operating lease right-of-use assets, net 7,633 10,674 Other assets 2,419 379 Available-for-sale securities, long-term 19,444 4,628 Equity investments — 995 Intangible assets, net 7,450 9,559 Goodwill 212,304 212,304 Total assets $ 392,081 $ 399,487 Liabilities and Shareholders ' Equity Current liabilities: Accounts payable $ 2,890 $ 3,573 Accrued expenses and other current liabilities 10,905 12,451 Sales taxes payable 3,681 4,256 Lease liabilities, operating, current portion 2,178 1,511 Debt, current portion 7,492 10,943 Total current liabilities 27,146 32,734 Lease liabilities, operating, long-term 11,007 12,723 Debt, long-term — 4,997 Deferred tax liabilities 189 124 Total liabilities 38,342 50,578 Commitments and contingencies (Note 12) Shareholders' equity: Preferred stock, $ 0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of September 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value; 150,000,000 shares authorized, 47,965,751 and 46,906,765 shares issued and outstanding, respectively, as of September 30, 2025 and December 31, 2024 48 47 Additional paid-in capital 704,327 683,939 Accumulated other comprehensive income, net of tax 130 24 Accumulated deficit ( 350,766 ) ( 335

Business

Business BioLife Solutions, Inc. ("BioLife", "us", "we", "our", or the "Company") is a life sciences company that develops, manufactures, and markets bioproduction products and services which are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. Our products include proprietary biopreservation media, automated thawing devices, and cloud-connected shipping containers. Our CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. These novel biopreservation media products are serum-free and protein-free, fully defined, and formulated to reduce preservation-induced cell damage and death. Our Sexton cell processing product line includes human platelet lysates ("hPL") for cell expansion, reducing risk and improving downstream performance over fetal bovine serum, human serum, and other chemically defined media, CellSeal cryogenic vials that are purpose-built rigid containers used in CGT that can be filled manually or with high throughput systems, CryoCase cryo-compatible transparent rigid containers designed for closed-system fill and retrieval, and automated cell processing machines that bring multiple processes traditionally performed by manual techniques under a higher level of control to protect therapies from loss or contamination. Our ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. These products help administer temperature-sensitive biologic therapies to patients by standardizing the thawing process and reducing the risks of contamination and overheating, which are inherent with the use of traditional water baths. Our evo shipping containers provide cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. On October 6, 2025, the Company entere

View Full Filing

View this 10-Q filing on SEC EDGAR